Assertio Therapeutics, Inc. buy Subdi
Start price
11.01.16
/
50%
€13.29
Target price
03.05.17
€25.26
Performance (%)
-25.39%
End price
03.05.17
€9.91
Summary
This prediction ended on 03.05.17 with a price of €9.91. The price of Assertio Therapeutics, Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.39%. Subdi has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Assertio Therapeutics, Inc. | -2.667% | -2.667% | -87.813% | -92.074% |
iShares Core DAX® | -0.621% | 1.080% | 11.291% | 16.439% |
iShares Nasdaq 100 | -4.503% | -5.432% | 22.172% | 39.304% |
iShares Nikkei 225® | -2.562% | -1.617% | 7.262% | 8.383% |
iShares S&P 500 | -1.706% | -1.223% | 22.550% | 40.997% |
Comments by Subdi for this prediction
In the thread Assertio Therapeutics, Inc. diskutieren
Subdi stimmt der Buy-Einschätzung von datca zu
Einer von drei aktuellen Biotech-Picks von Bret Jensen
Subdi stimmt am 11.01.2016 der Buy-Einschätzung von datca mit dem Kursziel 45$ zu.
Überschrift: Aussichtsreich, auch ohne Übernahme durch Horizon Pharma!
(Stop Loss Kurs erreicht)